Biomarkers /
TET2
Overview
Tet methylcytosine dioxygenase 2 (TET2; also known as ten-eleven translocation 2) is a gene that codes for methylcytosine dioxygenase TET2, a protein involved in epigenetic regulation of myelopoeisis (Gene 2014; PMID: 24220273). TET2 is a tumor suppressor, and so in cancer, loss of TET2 function, which can occur via TET2 mutation, TET2 deletion, or IDH1 or IDH2 mutation, can cause myeloid or lymphoid transformations (PMID: 24220273). Mutations in TET2 have been found in MDS, AML, ALL, and other hematologic malignancies.
TET2 is altered in 4.62% of all cancers with lung adenocarcinoma, colon adenocarcinoma, acute myeloid leukemia, myelodysplastic syndromes, and cutaneous melanoma having the greatest prevalence of alterations [3].
The most common alterations in TET2 are TET2 Mutation (3.76%), TET2 c.3310-c.4434 Missense (1.00%), TET2 Nonsense (0.97%), TET2 c.3400-c.4331 Missense (0.92%), and TET2 c.5533-c.6005 Missense (0.40%) [3].
Clinical Trials
Significance of TET2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.